AGM

ReNeuron Group plc
23 August 2006

                      ReNeuron 2006 Annual General Meeting

Guildford, UK, 23 August 2006: ReNeuron Group plc (LSE: RENE) today announces
that it has sent notice to its Shareholders and Warrant holders convening its
2006 Annual General Meeting (the AGM) and a meeting of its Warrant holders, each
meeting to be held on 21 September 2006.

The resolutions to be put to Warrant holders cover the proposed amendment of the
terms of the Warrants so as to reduce the price payable on exercise of the
Warrants from 30p per Ordinary Share to 10p per Ordinary Share and to shorten
the exercise period of the Warrants such that the end of the exercise period
will be brought forward from 12 February 2007 to 12 December 2006.

The resolutions to be put to Shareholders at the AGM cover:

•   the Annual Report and Accounts for the year ended 31 March 2006;

•   the reappointment of the Directors;

•   the reappointment of the auditors;

•   the subdivision of each of the Company's Ordinary Shares of 10p in nominal 
    value into one new Ordinary Share of 1p in nominal value and one
    Deferred Share of 9p in nominal value (and subsequent thereto the repurchase 
    and cancellation of all such Deferred Shares);

•   granting authority to issue new securities, including a proposed placing of 
    up to 100,000,000 Ordinary Shares (authority for such a proposed placing 
    having been previously granted at the extraordinary general meeting of the 
    Company held on 26 April 2006); and

•   approving the amendment of the Warrants as described above.

Enquiries:

ReNeuron
Michael Hunt, CEO                                    Tel: [phone]
John Sinden, CSO

Financial Dynamics
David Yates                                          Tel: [phone]
Sarah Macleod


Notes to Editors

ReNeuron is a leading, UK-based adult stem cell therapy business.  The Group is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.

ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.

The Group's lead stem cell therapy, ReN001 for chronic stroke disability, is in
late pre-clinical development.  Subject to successful completion of pre-clinical
testing, the Company plans to file for approval to commence a Phase I clinical
study in stroke by the end of 2006, with the study commencing as soon as
possible thereafter.

The Group has also generated pre-clinical efficacy data with its ReN005 stem
cell therapy for Huntington's disease, a rare, genetic and fatal
neurodegenerative disorder that affects around 1 in 10,000 people.  This
programme is in pre-clinical development.

In addition to its stroke and Huntington's disease programmes, ReNeuron is
developing stem cell therapies for Parkinson's disease, Type 1 diabetes and
diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell range of cell lines for use in drug discovery applications
in the pharmaceutical industry.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.

Further information on ReNeuron and its products can be found at
www.reneuron.com.

This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.


                      This information is provided by RNS
            The company news service from the London Stock Exchange